이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genetron Holdings 관리

관리 기준 확인 2/4

Genetron Holdings' CEO는 Sizhen Wang, May2015 에 임명되었습니다 의 임기는 8.92 년입니다. 는 $ 6.79M 가치에 해당하는 회사 주식의 5.33% 직접 소유합니다. 6.79M. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 3.8 년입니다.

주요 정보

Sizhen Wang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	8.9yrs
CEO 소유권	5.3%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 17

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Mar 27

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

Feb 25

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

Jan 06

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

Nov 27

Genetron (GTH) Investor Presentation - Slideshow

Nov 18

Genetron Holdings reports Q3 results

Nov 09

CEO

Sizhen Wang (45 yo)

8.9yrs

테뉴어

Mr. Sizhen Wang has been Chairman at Genetron Holdings Limited since June 2021. He is the Co-Founder of Genetron Holdings Limited. He has been Director at Genetron Holdings Limited since April 2018 and has...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sizhen Wang	Co-Founder	8.9yrs	데이터 없음	5.33% CN¥ 6.8m
Wei-Wu He	Co-Founder & Chairman Emeritus	no data	데이터 없음	4.3% CN¥ 5.5m
Hai Yan	Co-Founder	no data	데이터 없음	6.99% CN¥ 8.9m
Ce Xu	Chief Financial Officer	6.1yrs	데이터 없음	데이터 없음
Victoria Lei	Chief Operating Officer	1.8yrs	데이터 없음	데이터 없음
Yuchen Jiao	Chief Technology Officer	6.7yrs	데이터 없음	0.78% CN¥ 989.3k
Yong Liang	Chief Human Resources Officer	2.3yrs	데이터 없음	데이터 없음
Yun-Fu Hu	Chief Medical Officer	4yrs	데이터 없음	데이터 없음
Lily Liu	Chief Commercial Officer	1.8yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: GTH 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sizhen Wang	Co-Founder	6yrs	데이터 없음	5.33% CN¥ 6.8m
Wei-Wu He	Co-Founder & Chairman Emeritus	2.8yrs	데이터 없음	4.3% CN¥ 5.5m
Hai Yan	Co-Founder	no data	데이터 없음	6.99% CN¥ 8.9m
Dian Kang	Independent Director	3.8yrs	데이터 없음	데이터 없음
Webster Cavenee	Independent Director	3.8yrs	데이터 없음	데이터 없음
Wing Kee Lau	Independent Director	3.8yrs	데이터 없음	데이터 없음
Shan Fu	Non Executive Director	2.8yrs	데이터 없음	데이터 없음
Xia Wu	Non-Executive Director	6.6yrs	데이터 없음	데이터 없음
Chao Tang	Non Executive Director	2.8yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: GTH 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Genetron Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Recent updates

Genetron Holdings Files Form 15

Genetron Holdings Requests Nasdaq to File Form 25 with the Securities and Exchange Commission for Delisting of the ADSs on Nasdaq and the Deregistration of its Registered Securities

New minor risk - Shareholder dilution

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genetron Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Less than half of directors are independent

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Minimum Bid Price

Second quarter 2022 earnings released: CN¥2.54 loss per share (vs CN¥1.00 loss in 2Q 2021)

Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M

Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited (NasdaqGM:GTH) from Genetron Health (Hong Kong) Company Limited and others for $60 million.

China's Genetron gets acquisition offer from co-founder/CEO

Genetron Holdings Limited to Report Q1, 2022 Results on Jun 02, 2022

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to US$6.51

Consensus EPS estimates fall by 24%

Less than half of directors are independent

Consensus EPS estimates fall by 24%

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Genetron Holdings Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2021

Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$18.92

Genetron Holdings Limited Provides Revenue Guidance for the Full Year 2021

Price target decreased to US$22.63

Co-Founder notifies of intention to sell stock

Second quarter 2021 earnings released

Genetron Holdings Limited Maintains Revenue Guidance for the Year 2021

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Genetron Health Limited Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Chief Operating Officer Ying Hong has left the company

Non-Executive Director Weidong Liu has left the company

Genetron Holdings Limited Reiterates 2021 Financial Guidance

First quarter 2021 earnings released: CN¥1.23 loss per share (vs CN¥4.62 loss in 1Q 2020)

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Consensus forecasts updated

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Genetron Holdings Limited Provides Revenue Guidance for Year 2021

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Genetron Holdings Limited to Report Q4, 2020 Results on Mar 25, 2021

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

New 90-day high: US$28.04

New 90-day high: US$23.47

Genetron Health Announces Exclusive Strategic Partnership with Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

New 90-day high: US$14.00

Genetron Holdings Limited Provides an Update for Hccscreentm, Its Blood-Based Early Screening Test for Hepatocellular Carcinoma (“Hcc”), in China

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

New 90-day high: US$13.27

Genetron (GTH) Investor Presentation - Slideshow

Analysts increase EPS estimates to -CN¥10.14

Genetron Holdings reports Q3 results

Genetron Holdings Limited to Report Q3, 2020 Results on Nov 09, 2020

Genetron Holdings Limited Receives U.S. FDA Breakthrough Device Designation for its Blood-based NGS Test for Early Detection of Hepatocellular Carcinoma

Genetron Holdings Limited and Cstone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in Development for Avapritinib

New 90-day low: US$10.80

Genetron Health and Dmed Announce Partnership Agreement

First half earnings released

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령